{
    "info": {
        "nct_id": "NCT04150887",
        "official_title": "An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia",
        "inclusion_criteria": "* Diagnosis of acute myeloid leukemia (AML) according to World Health Organization 2016 criteria . Participants with acute promyelocytic leukemia (APL) are not eligible\n* Must be ineligible for intensive chemotherapy\n* De novo or secondary AML\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n* Previously untreated AML except: emergency leukapheresis, hydroxyurea, and/or 1 dose 1-2 gram per meter square (g/m^2) cytarabine during the Screening Phase to control hyperleukocytosis. These treatments must be discontinued greater than or equal to (>=) 24 hours prior to start of study drug. Empiric all trans retinoic acid (ATRA) treatment for presumed acute promyelocytic leukemia (APL) is permitted but APL must be ruled out and ATRA must be discontinued >=24 hours prior to the start of study drug\n* Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Leukemic involvement of the central nervous system\n* Eligible for an allogeneic hematopoietic stem cell transplantation at study entry\n* Received a live, attenuated vaccine within 4 weeks prior to initiation of study drug\n* A history of human immunodeficiency virus (HIV) antibody positive or tests positive for HIV if tested at screening\n* Known allergies, hypersensitivity, or intolerance to cusatuzumab, venetoclax, azacitidine, or their excipients (example: mannitol, an excipient of azacitidine)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of acute myeloid leukemia (AML) according to World Health Organization 2016 criteria . Participants with acute promyelocytic leukemia (APL) are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of acute myeloid leukemia (AML) according to World Health Organization 2016 criteria",
                    "criterion": "acute myeloid leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "World Health Organization 2016"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with acute promyelocytic leukemia (APL) are not eligible",
                    "criterion": "acute promyelocytic leukemia (APL) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must be ineligible for intensive chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Must be ineligible for intensive chemotherapy",
                    "criterion": "eligibility for intensive chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* De novo or secondary AML",
            "criterions": [
                {
                    "exact_snippets": "De novo or secondary AML",
                    "criterion": "acute myeloid leukemia (AML) type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "de novo",
                                "secondary"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies",
            "criterions": [
                {
                    "exact_snippets": "Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "consistency with local regulations",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previously untreated AML except: emergency leukapheresis, hydroxyurea, and/or 1 dose 1-2 gram per meter square (g/m^2) cytarabine during the Screening Phase to control hyperleukocytosis. These treatments must be discontinued greater than or equal to (>=) 24 hours prior to start of study drug. Empiric all trans retinoic acid (ATRA) treatment for presumed acute promyelocytic leukemia (APL) is permitted but APL must be ruled out and ATRA must be discontinued >=24 hours prior to the start of study drug",
            "criterions": [
                {
                    "exact_snippets": "Previously untreated AML except: emergency leukapheresis, hydroxyurea, and/or 1 dose 1-2 gram per meter square (g/m^2) cytarabine during the Screening Phase to control hyperleukocytosis.",
                    "criterion": "acute myeloid leukemia (AML) treatment history",
                    "requirements": [
                        {
                            "requirement_type": "previous treatment",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "allowed exceptions",
                            "expected_value": [
                                "emergency leukapheresis",
                                "hydroxyurea",
                                "1 dose 1-2 g/m^2 cytarabine during Screening Phase to control hyperleukocytosis"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "These treatments must be discontinued greater than or equal to (>=) 24 hours prior to start of study drug.",
                    "criterion": "prior allowed AML treatments",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation time before study drug",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Empiric all trans retinoic acid (ATRA) treatment for presumed acute promyelocytic leukemia (APL) is permitted but APL must be ruled out and ATRA must be discontinued >=24 hours prior to the start of study drug",
                    "criterion": "all trans retinoic acid (ATRA) treatment for presumed APL",
                    "requirements": [
                        {
                            "requirement_type": "APL diagnosis",
                            "expected_value": "must be ruled out"
                        },
                        {
                            "requirement_type": "ATRA discontinuation time before study drug",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Received a live, attenuated vaccine within 4 weeks prior to initiation of study drug",
            "criterions": [
                {
                    "exact_snippets": "Received a live, attenuated vaccine within 4 weeks prior to initiation of study drug",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks prior to initiation of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Leukemic involvement of the central nervous system",
            "criterions": [
                {
                    "exact_snippets": "Leukemic involvement of the central nervous system",
                    "criterion": "central nervous system leukemic involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known allergies, hypersensitivity, or intolerance to cusatuzumab, venetoclax, azacitidine, or their excipients (example: mannitol, an excipient of azacitidine)",
            "criterions": [
                {
                    "exact_snippets": "Known allergies ... to cusatuzumab, venetoclax, azacitidine, or their excipients",
                    "criterion": "allergies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "substances",
                            "expected_value": [
                                "cusatuzumab",
                                "venetoclax",
                                "azacitidine",
                                "their excipients"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Known ... hypersensitivity ... to cusatuzumab, venetoclax, azacitidine, or their excipients",
                    "criterion": "hypersensitivity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "substances",
                            "expected_value": [
                                "cusatuzumab",
                                "venetoclax",
                                "azacitidine",
                                "their excipients"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Known ... intolerance to cusatuzumab, venetoclax, azacitidine, or their excipients",
                    "criterion": "intolerance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "substances",
                            "expected_value": [
                                "cusatuzumab",
                                "venetoclax",
                                "azacitidine",
                                "their excipients"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eligible for an allogeneic hematopoietic stem cell transplantation at study entry",
            "criterions": [
                {
                    "exact_snippets": "Eligible for an allogeneic hematopoietic stem cell transplantation at study entry",
                    "criterion": "allogeneic hematopoietic stem cell transplantation eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at study entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A history of human immunodeficiency virus (HIV) antibody positive or tests positive for HIV if tested at screening",
            "criterions": [
                {
                    "exact_snippets": "A history of human immunodeficiency virus (HIV) antibody positive",
                    "criterion": "HIV antibody status",
                    "requirements": [
                        {
                            "requirement_type": "history of positivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tests positive for HIV if tested at screening",
                    "criterion": "HIV status at screening",
                    "requirements": [
                        {
                            "requirement_type": "positivity at screening",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}